Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis-Reference-Cited by-同舟云学术

Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis

Published:2023-11 Issue:6 Volume:75 Page:416-422
ISSN:0019-4832
Container-title:Indian Heart Journal
language:en
Short-container-title:Indian Heart Journal

Author:

Nagendra Lakshmi,Mahajan Kunal,Gupta Gunjan,Dutta Deep^ORCID

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference27 articles.

1. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. Results from the PROVE IT-TIMI 22 trial;Ray;J Am Coll Cardiol,2005

3. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol;Grundy;J Am Coll Cardiol,2018

4. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries. Findings from the EUROASPIRE IV survey;Reiner;Atherosclerosis,2016

5. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis;European Journal of Internal Medicine;2024-06